Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure

Circulation

Volumn 112, Issue 6, 2005, Pages 836-840

  Cataliotti, Alessandro ^a   Schirger, John A ^a   Martin, Fernando L ^a   Chen, Horng H ^a   McKie, Paul M ^a   Boerrigter, Guido ^a   Costello Boerrigter, Lisa C ^a   Harty, Gail ^a   Heublein, Denise M ^a   Sandberg, Sharon M ^a   James, Kenneth D ^b   Miller, Mark A ^b   Malkar, Navdeep B ^b   Polowy, Karen ^b   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

^b Nobex Corporation   (United States)

Author keywords

Blood pressure; Cyclic GMP; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CONJUGATED HUMAN BRAIN NATRIURETIC PEPTIDE 021; CYCLIC GMP; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVALENT BOND; CROSSOVER PROCEDURE; DOG; DOSE TIME EFFECT RELATION; DRUG CONJUGATION; DRUG MECHANISM; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OLIGOMERIZATION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; CROSS-OVER STUDIES; CYCLIC GMP; DOGS; HUMANS; HYPOTENSION; MALE; MODELS, ANIMAL; NATRIURETIC PEPTIDE, BRAIN;

EID: 23844481859     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.538520     Document Type: Article

References (23)

1. Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, Hosoda K, Shirakami G, Suga S, Minamino N. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 1989;158:360-368.
2. Kambayashi Y, Nakao K, Mukoyama M, Saito Y, Ogawa Y, Shiono S, Inouye K, Yoshida N, Imura H. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. 1990;259:341-345.
3. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-412.
4. Yan W, Sheng N, Seto M, Morser J, Wu Q. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem. 1999;274:14926-14935.
5. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000;97:8525-8529.
6. Hooper JD, Scarman AL, Clarke BE, Normyle JF, Antalis TM. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem. 2000;267:6931-6937.
7. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328.
8. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680-1685.
9. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
10. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
11. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure: Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
12. Yancy CW, Saltzberg MT, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, Silver MA. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION 1 trial). Am J Cardiol. 2004;94:595-601.
13. Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res. 2004;21:2105-2111.
14. James KD, Radhakrishnan B, Malkar NB, Miller MA, Ekwuribe NM. Preparation of modified natriuretic conjugates. Chem Abstr. 2004;141:38847.
15. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC Jr. Natriuretic and anti-aldosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005;67:1723-1730.
16. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147.
17. Grantham JA, Borgeson DD, Burnett JC Jr, BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol. 1997;272(pt 2):R1077-R1083.
18. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, Schaff HV, Burnett JC Jr. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004-1009.
19. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, Tahara A, Toda I, Takeuchi K, Kurihara N. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 1992;92:29-34.
20. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Integr Comp Physiol. 2005;288:R1093-R1097.
21. Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol. 2000;36:1706-1712.
22. Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett JC Jr. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004;10:115-119.
23. Morcol T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJ. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int J Pharm. 2004;277:91-97.